Global development of bispecific antibodies (BsAbs) and bispecific antibody-drug conjugates (BsADCs) is undergoing explosive growth. However, key pain points persist—heavy-light chain mismatch, inadequate target synergy, poor toxicity control, and complex manufacturing. While novel technologies have been developed to address these issues, drug development still faces hurdles in target combination selection, lengthy antibody discovery cycles, and low clinical translation success rates.
Biocytogen RenLite® mice generate fully human antibody candidates with a common light chain, enabling subsequent assembly of BsAbs with minimized chain mismatch and excellent developability—conferring advantages for downstream CMC development. Additionally, the common light chain facilitates screening of different BsAb formats, payload conjugation, and function evaluation—supporting the discovery of diverse BsAb or BsAb-ADC modalities.
To date, leveraging RenLite® and its novel BsADC platform, Biocytogen has generated multiple preclinical BsAb-ADC candidates. For example, DM001 (anti-TROP2×EGFR), with good developability, demonstrates potent tumor-suppressive activity in seven various patient-derived xenograft (PDX) models; DM005 (anti-EGFR×MET), with high purity and good conjugation property, exhibits outstanding specificity and anti-tumor efficacy in lung cancer PDX models. These BsADC candidates hold great clinical development potential.
Leveraging its RenLite® platform and preliminary screening, Biocytogen has built an antibody library covering over 200 tumor-associated antigens (TAAs). This lets researchers easily conduct rapid screening, flexible pairing, and target synergy validation using in vitro/in vivo efficacy platforms, speeding up BsAb/ BsADC development and boosting clinical translation success of anticancer therapies.
